TOKYO -- Japanese pharmaceutical company Eisai is developing an Alzheimer's disease treatment that targets a protein linked to symptoms, aiming to release it in the U.S. by fiscal 2030, Nikkei has learned.
Pharmaceuticals
Japan's Eisai aims for 2030 U.S. release of new Alzheimer's drug
Pharma hopes to use in combination with lecanemab for greater effectiveness
Japanese company Eisai currently has the only approved Alzheimer's treatment on the market. (Photo by Aya Onishi)
Read Next
Latest on Pharmaceuticals
